XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
3 Months Ended
Oct. 31, 2023
Fair Value Measurements [Abstract]  
Schedule of Assets Required to be Measured at Fair Value on a Recurring Basis The following is a listing of the Company’s assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of October 31, 2023 and July 31, 2023:
   October 31, 2023 
   Level 1   Level 2   Level 3   Total 
Assets:  (in thousands) 
Available-for-sale securities - Corporate Bonds  $
   $46,476   $
   $46,476 
Available-for-sale securities - U.S. Treasury Bills   12,418    
    
    12,418 
Investment in Cyclo Therapeutics Inc. - Common Stock   8,759    
    
    8,759 
Investment in Cyclo Therapeutics Inc. - Warrants   
    
    1,090    1,090 
Hedge funds   
    
    2,318    2,318 
Convertible note receivable, related party   
    
    1,858    1,858 
Total  $21,177   $46,476   $5,266   $72,919 
   July 31, 2023 
   Level 1   Level 2   Level 3   Total 
Assets:  (in thousands) 
Available-for-sale securities - Corporate Bonds  $
   $46,439   $
   $46,439 
Available-for-sale securities - U.S. Treasury Bills   11,275    
    
    11,275 
Investment in equity securities   294    
    
    294 
Investment in Cyclo Therapeutics Inc. - Common Stock   3,898    
    
    3,898 
Investment in Cyclo Therapeutics Inc. - Warrants   865    
    
    865 
Hedge funds   
    
    4,984    4,984 
Convertible note receivable, related party   
    
    1,921    1,921 
Total  $16,332   $46,439   $6,905   $69,676 
Schedule of Fair Value Assets Measured at Fair Value on a Recurring Basis The following table summarizes the changes in the fair value of the assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
   Three Months Ended
October 31,
 
   2023   2022 
   (in thousands) 
Balance, beginning of period  $6,905   $4,764 
Withdrawal from Hedge Fund Investments   (2,500)   
 
Unrealized loss on Hedge Fund   (166)   (127)
Investment in Cyclo Warrants   1,338    
 
Unrealized loss on Cyclo Warrants   (248)   
 
 
Unrealized loss on Convertible Note Receivable, Related Party   (63)   
 
Balance, end of period  $5,266   $4,637 
Schedule of Unobservable Inputs to the Cyclo Warrants Below are the unobservable inputs to the Cyclo Warrants which reflect a Level 3 measurement within the fair value measurement hierarchy as of October 31, 2023:
Unobservable Input  Range  Weighted Average
Price Per Share [1]  $0.49 - $0.58  $0.54
Exercise Price  $0.95 - $1.25  $1.10
Expected Volatility  82.2% - 85.5%  84.0%
Risk - Free Rate [2]  4.90%  4.90%
Marketability Discount  45.0% - 50.0%  48.0%
Remaining Term  3.97 to 6.75 years  5.36 years
Fair Value per Warrant [3]  $0.15 - $0.18  $0.17
[1]Closing price of Cyclo’s common shares adjusted to reflect regulatory resale restrictions which ranged from 40.0% to 50.0%
[2]US Treasury rate for a period commensurate with the Remaining Term.
[3]Concluded fair value per warrant as of October 31, 2023